|
Market Closed -
Nasdaq
16:00:00 2026-11-03 EST
|
5-day change | 1st Jan Change | ||
| 530.76 USD | -4.05% |
|
+1.87% | +17.07% |
| 11-03 | Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says | MT |
| 11-03 | UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615, Maintains Buy Rating | MT |
| Market Cap | 135B 120B 110B 100B 188B 12,743B 193B 1,318B 530B 6,726B 505B 494B 21,318B | P/E 2026 * |
34.7x | P/E 2027 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 132B 118B 108B 98.21B 184B 12,482B 189B 1,291B 519B 6,588B 495B 484B 20,881B | EV / Sales 2026 * |
9.94x | EV / Sales 2027 * | 8.8x |
| Free-Float |
99.77% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
Tradegate
| VX1 | Real-time | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
CBOE
| Real-time | ||
|
London S.E.
| 0QZU | Delayed | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
Xetra
| VX1 | Delayed | |
|
CBOE
| 0QZU | Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -4.05% | ||
| 1 week | +1.87% | ||
| Current month | -5.03% | ||
| 1 month | +5.16% | ||
| 3 months | +12.75% | ||
| 6 months | +25.20% | ||
| Current year | +17.07% |
| 1 week | 529.15 |  | 568.67 |
| 1 month | 484.08 | | 568.67 |
| Current year | 412.27 | | 568.67 |
| 1 year | 406.67 | | 568.67 |
| 3 years | 341.9 | | 568.67 |
| 5 years | 179.96 | | 568.67 |
| 10 years | 71.46 | | 568.67 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Agam Upadhyay
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/28/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 8/27/26 | Don | Director | -6,000 | 0.0024% | ||
| 7/21/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.05% | +1.87% | +24.59% | +41.08% | 135B | |
| -0.11% | +9.94% | +57.20% | +148.21% | 1,255B | |
| -1.62% | -0.95% | +42.90% | +75.88% | 641B | |
| -0.98% | -0.14% | +34.93% | +102.23% | 505B | |
| -0.04% | -1.78% | +48.37% | +65.17% | 381B | |
| -2.49% | +2.01% | +75.38% | +39.94% | 357B | |
| +0.30% | +2.23% | +30.17% | +56.81% | 303B | |
| -0.94% | +6.96% | +8.97% | +32.85% | 286B | |
| -0.90% | +2.97% | +55.67% | +70.93% | 249B | |
| -1.68% | +5.27% | +37.21% | +105.26% | 208B | |
| Average | -1.26% | +2.84% | +41.54% | +73.84% | 431.98B | |
| Weighted average by Cap. | -0.90% | +3.84% | +46.04% | +91.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.25B 11.84B 10.88B 9.88B 18.55B 1,255B 19.01B 130B 52.22B 663B 49.74B 48.68B 2,100B | 14.65B 13.09B 12.02B 10.92B 20.5B 1,387B 21.01B 143B 57.72B 732B 54.98B 53.8B 2,321B |
| Net income | 3.94B 3.52B 3.23B 2.94B 5.51B 373B 5.65B 38.58B 15.52B 197B 14.78B 14.47B 624B | 4.65B 4.16B 3.82B 3.47B 6.51B 441B 6.68B 45.59B 18.34B 233B 17.47B 17.1B 738B |
| Net Debt | -2.76B -2.46B -2.26B -2.06B -3.86B -261B -3.96B -27.02B -10.87B -138B -10.36B -10.13B -437B | -5.7B -5.1B -4.68B -4.25B -7.98B -540B -8.18B -55.87B -22.48B -285B -21.41B -20.95B -904B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-03 | US$530.76 | -4.05% | 2,373,648 |
| 26-11-02 | US$553.15 | -1.03% | 3,208,364 |
| 26-10-30 | US$558.88 | +3.50% | 3,030,027 |
| 26-10-29 | US$540.00 | +1.95% | 1,542,075 |
| 26-10-28 | US$529.69 | +1.66% | 1,284,581 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
